A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder (NCT07252908) | Clinical Trial Compass
CompletedPhase 2
A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder
China195 participantsStarted 2025-12-22
Plain-language summary
To evaluate the efficacy and safety of TQC3721 inhalation powder in patients with moderate to severe Chronic obstructive pulmonary disease (COPD).
Who can participate
Age range
40 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Exclusion criteria
. Myocardial infarction, unstable angina, or stroke within the past 6 months;
. Unstable or life-threatening arrhythmias requiring intervention within the past 3 months;
. New York Heart Association (NYHA) Class III-IV heart failure.
. Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) \> 2 × Upper Limit of Normal (ULN); alkaline phosphatase \> 2 × ULN; total bilirubin \> 1.5 × ULN;
. Estimated glomerular filtration rate (eGFR) calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula \< 60 mL/min/1.73m².
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this is a Phase II trial of TQC3721 inhalation powder, what does that phase tell us about how much is still unknown regarding its safety and effectiveness compared to COPD inhalers I could use right now?
2This trial measured changes in FEV1 — the amount of air I can forcefully exhale in one second — as its main outcome; based on the results, how meaningful were the improvements seen, and would they make a noticeable difference in my day-to-day breathing?
3Since this trial has already been completed, would I be able to access the published results, and do those results suggest TQC3721 performed better, worse, or about the same as existing COPD treatments I might already qualify for?
4Given that this involved an inhalation powder delivered in a specific way, is there anything about my current lung function or inhaler technique that would affect whether a treatment like this could even work well for me?
5Before considering any experimental option like this one, would it make more sense to first try standard COPD therapies such as established long-acting bronchodilators, and what would help us decide between those paths?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change of the maximum value of Forced Expiratory Volume in the first second (FEV1)
Timeframe: From baseline to four weeks after treatment
Trial details
NCT IDNCT07252908
SponsorChia Tai Tianqing Pharmaceutical Group Co., Ltd.